Coral Laboratories (CORALAB) | Financial Analysis & Statements
Coral Laboratories Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
188.2M
Gross Profit
100.8M
53.58%
Operating Income
17.3M
9.19%
Net Income
25.6M
13.62%
EPS (Diluted)
₹7.18
Balance Sheet Metrics
Total Assets
2.3B
Total Liabilities
282.6M
Shareholders Equity
2.0B
Debt to Equity
0.14
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Coral Laboratories Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 821.0M | 778.9M | 732.2M | 952.1M |
| Cost of Goods Sold | 561.9M | 403.4M | 492.6M | 426.4M | 537.4M |
| Gross Profit | 569.9M | 417.5M | 286.3M | 305.8M | 414.7M |
| Gross Margin % | 50.4% | 50.9% | 36.8% | 41.8% | 43.6% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 69.2M | 61.9M | 31.1M | 47.0M | 82.6M |
| Other Operating Expenses | 97.4M | 79.0M | 83.5M | 82.2M | 81.4M |
| Total Operating Expenses | 166.6M | 140.9M | 114.5M | 129.2M | 164.0M |
| Operating Income | 246.1M | 142.6M | 16.3M | 62.2M | 138.7M |
| Operating Margin % | 21.7% | 17.4% | 2.1% | 8.5% | 14.6% |
| Non-Operating Items | |||||
| Interest Income | 48.4M | 33.6M | 17.9M | 17.5M | 20.4M |
| Interest Expense | 976.0K | 2.0K | 3.4M | 1.4M | 425.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 324.7M | 207.3M | 82.3M | 118.6M | 176.1M |
| Income Tax | 83.1M | 49.4M | 17.8M | 28.1M | 40.6M |
| Effective Tax Rate % | 25.6% | 23.8% | 21.6% | 23.7% | 23.0% |
| Net Income | 241.6M | 157.9M | 64.5M | 90.5M | 135.5M |
| Net Margin % | 21.3% | 19.2% | 8.3% | 12.4% | 14.2% |
| Key Metrics | |||||
| EBITDA | 353.5M | 228.7M | 107.1M | 130.3M | 196.2M |
| EPS (Basic) | ₹67.61 | ₹44.19 | ₹18.04 | ₹25.32 | ₹37.94 |
| EPS (Diluted) | ₹67.61 | ₹44.19 | ₹18.04 | ₹25.32 | ₹37.94 |
| Basic Shares Outstanding | 3572600 | 3572600 | 3572600 | 3572600 | 3572600 |
| Diluted Shares Outstanding | 3572600 | 3572600 | 3572600 | 3572600 | 3572600 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Coral Laboratories Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 34.1M | 20.7M | 61.3M | 25.1M | 23.2M |
| Short-term Investments | 275.4M | 257.2M | 238.8M | 217.6M | 190.8M |
| Accounts Receivable | 336.4M | 281.9M | 234.2M | 381.1M | 391.6M |
| Inventory | 98.7M | 151.6M | 125.0M | 183.6M | 216.7M |
| Other Current Assets | 101.0K | 1.0K | 211.2M | 1.0K | -46.0K |
| Total Current Assets | 1.8B | 1.5B | 1.2B | 1.3B | 1.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 217.4M | 232.7M | 242.8M | 227.7M | 204.1M |
| Goodwill | 674.0K | 632.0K | 177.0K | 186.0K | 254.0K |
| Intangible Assets | 674.0K | 632.0K | 177.0K | 186.0K | 254.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.0K | 10.6M | 1.0K | -1.0K | -2.0K |
| Total Non-Current Assets | 529.2M | 518.3M | 508.1M | 590.9M | 389.2M |
| Total Assets | 2.3B | 2.1B | 1.7B | 1.9B | 1.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 66.2M | 132.4M | 42.1M | 88.0M | 147.8M |
| Short-term Debt | 35.6M | 0 | 0 | 60.4M | 62.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 673.0K | 2.7M | 654.0K | 1.5M | 2.6M |
| Total Current Liabilities | 249.6M | 249.0M | 118.6M | 255.2M | 275.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 25.5M | 25.7M | 25.4M | 25.8M | 25.2M |
| Other Non-Current Liabilities | -1.0K | - | - | 2.0K | 2.1M |
| Total Non-Current Liabilities | 33.0M | 32.8M | 76.9M | 83.3M | 33.3M |
| Total Liabilities | 282.6M | 281.8M | 195.5M | 338.4M | 309.0M |
| Equity | |||||
| Common Stock | 35.7M | 35.7M | 35.7M | 35.7M | 35.7M |
| Retained Earnings | 1.7B | 1.5B | 1.3B | 1.3B | 1.2B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.0B | 1.8B | 1.5B | 1.6B | 1.4B |
| Key Metrics | |||||
| Total Debt | 35.6M | 0 | 0 | 60.4M | 62.5M |
| Working Capital | 1.5B | 1.3B | 1.1B | 1.1B | 1.0B |
Balance Sheet Composition
Coral Laboratories Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 332.4M | 209.0M | 81.9M | 109.0M | 175.9M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -178.5M | -236.0M | 106.7M | 4.0M | -139.4M |
| Operating Cash Flow | 106.4M | -60.6M | 174.1M | 96.8M | 16.5M |
| Investing Activities | |||||
| Capital Expenditures | -29.4M | -9.9M | -19.5M | -55.5M | -13.6M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -4.3M | 0 | -20.0M | -20.3M | 0 |
| Investment Sales | 0 | 1.8M | 2.7M | 0 | - |
| Investing Cash Flow | -52.7M | -21.7M | -46.2M | -81.9M | -22.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -7.1M | - | - | - | - |
| Debt Issuance | - | - | - | - | 3.4M |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 28.1M | - | - | -1.0K | 6.8M |
| Free Cash Flow | -41.7M | -64.6M | 107.2M | 5.4M | -4.3M |
| Net Change in Cash | 81.8M | -82.3M | 127.9M | 14.9M | 893.0K |
Cash Flow Trend
Coral Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
11.06
Forward P/E
7.45
Price to Book
0.73
Price to Sales
1.77
PEG Ratio
-0.20
Profitability Ratios
Profit Margin
15.97%
Operating Margin
5.58%
Return on Equity
12.01%
Return on Assets
10.53%
Financial Health
Current Ratio
10.03
Debt to Equity
0.41
Beta
0.90
Per Share Data
EPS (TTM)
₹39.14
Book Value per Share
₹596.42
Revenue per Share
₹245.07
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CORALAB | 1.5B | 11.06 | 0.73 | 12.01% | 15.97% | 0.41 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





